SNPMiner Trials (Home Page)
Report for Mutation L24E
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There is one clinical trial.
Clinical Trials
1 Influence of Corifollitropin Alfa (Elonva) on Embryo Morphokinetics and Fertility Treatment Outcome
The study evaluates the influence of corifollitropin alfa (Elonva) on embryo morphokinetics and fertility treatment outcome in comparison to a control group stimulated with Follitropin beta (Puregon).
NCT04142190 Infertility Drug: ELONVA Drug: PUREGON MeSH:Infertility
HPO:Infertility
Follicular fluid (FF) were examined for oocytes under constant conditions of 37 °C in an IVF workstation L24E with heating stage (K-SYSTEMS Kivex Biotec A/S). --- L24E ---
Primary Outcomes
Description: Time of pronuclei disappearance in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON
Measure: Time of pronuclei disappearance Time: 16-18 hours after fertilizationDescription: The first observation of two discrete cells in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON
Measure: Two discrete cells Time: 26-28 hours after fertilizationDescription: The first observation of three discrete cells in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON
Measure: Three discrete cells Time: 28-44 hours after fertilizationDescription: The first observation of four discrete cells in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON
Measure: Four discrete cells Time: 44-45 hours after fertilizationDescription: The first observation of five discrete cells in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON
Measure: Five discrete cells Time: 44-68 hours after fertilizationDescription: The first observation of six discrete cells in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON
Measure: Six discrete cells Time: 44-68 hours after fertilizationDescription: The first observation of seven discrete cells in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON
Measure: Seven discrete cells Time: 44-68 hours after fertilizationDescription: The first observation of eight discrete cells in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON
Measure: Eight discrete cells Time: 68-69 hours after fertilizationDescription: The first observation of nine discrete cells in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON
Measure: Nine discrete cells Time: 69-92 hours after fertilizationDescription: End of the compaction process; when observable compaction is complete in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON
Measure: Morula stage Time: 92 hours after fertilizationSecondary Outcomes
Description: The influence of ELONVA versus PUREGON on the number of oocytes retrieved will be assessed.
Measure: Number of oocytes retrieved Time: Number of oocytes retrieved will be evaluated after one treatment cycle (each cycle is between 28 and 35 days)Description: The influence of ELONVA versus PUREGON on the maturity stage of oocytes (germinal vesicle, metaphase I (MI) or MII phase) retrieved will be assessed.
Measure: Stage of oocyte development Time: Stage of oocytes retrieved will be evaluated after one treatment cycle (each cycle is between 28 and 35 days)Description: The influence of ELONVA versus PUREGON on the number of fertilized oocytes will be assessed.
Measure: Fertilized oocytes Time: Number of fertilized oocytes will be evaluated after one treatment cycle (each cycle is between 28 and 35 days)Description: The influence of ELONVA versus PUREGON on embryo grading (Istanbul consensus criteria) will be assessed. The grading consists of assessment of cell number, fragmentation, multinucleation, cell size, cytoplasmic granularity, membrane appearance, and the presence of vacuoles).
Measure: Embryo grading Time: The quality of embryos will be evaluated after one treatment cycle (each cycle is between 28 and 35 days)Description: The influence of Elonva versus Puregon on the number of biochemical pregnancies will be assessed.
Measure: Biochemical pregnancy (measurement of beta hCG) Time: Biochemical pregnancies will be evaluated after successful implantation (1 week after embryo transfer)Description: The influence of Elonva versus Puregon on the number of life births will be assessed.
Measure: Life birth Time: Life births will be evaluated after successful pregnancy (9 moths after embryo transfer)Description: The influence of Elonva versus Puregon on the weight of the newborn will be assessed.
Measure: Weight (kilograms) Time: Weight of the newborn will be evaluated after birth (9 moths after embryo transfer)Description: The influence of Elonva versus Puregon on the height of the newborn will be assessed.
Measure: Height (centimeters) Time: Height of the newborn will be evaluated after birth (9 moths after embryo transfer)